WO1992007830A3 - Oxindole peptide antagonists - Google Patents

Oxindole peptide antagonists Download PDF

Info

Publication number
WO1992007830A3
WO1992007830A3 PCT/US1991/004978 US9104978W WO9207830A3 WO 1992007830 A3 WO1992007830 A3 WO 1992007830A3 US 9104978 W US9104978 W US 9104978W WO 9207830 A3 WO9207830 A3 WO 9207830A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxindole
peptide antagonists
formula
antagonists
peptide
Prior art date
Application number
PCT/US1991/004978
Other languages
French (fr)
Other versions
WO1992007830A2 (en
Inventor
Susumu Nakanishi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of WO1992007830A2 publication Critical patent/WO1992007830A2/en
Publication of WO1992007830A3 publication Critical patent/WO1992007830A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Oxindole peptide antagonists have formula (I), wherein R2 is =CH-Ar or spirohydantoin, and R1, R3 and R4 are as defined herein. The compounds of formula (I) are of use in the treatment of small cell mammalian cancers.
PCT/US1991/004978 1990-10-29 1991-07-18 Oxindole peptide antagonists WO1992007830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60522090A 1990-10-29 1990-10-29
US605,220 1990-10-29

Publications (2)

Publication Number Publication Date
WO1992007830A2 WO1992007830A2 (en) 1992-05-14
WO1992007830A3 true WO1992007830A3 (en) 1992-06-25

Family

ID=24422724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004978 WO1992007830A2 (en) 1990-10-29 1991-07-18 Oxindole peptide antagonists

Country Status (3)

Country Link
IE (1) IE913732A1 (en)
PT (1) PT99350A (en)
WO (1) WO1992007830A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694004B1 (en) * 1992-07-21 1994-08-26 Adir News 3- (Hydroxybenzylidenyl) -indoline-2-ones and 3- (hydroxybenzylidenyl) -indoline-2-thiones, methods of preparation, and pharmaceutical compositions containing them.
JP3419539B2 (en) 1993-02-17 2003-06-23 中外製薬株式会社 Indoline-2-one derivatives
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO1997025986A1 (en) * 1996-01-17 1997-07-24 Taiho Pharmaceutical Co., Ltd. Intimal thickening inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
WO1999048868A2 (en) * 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
BR9910792A (en) 1998-05-29 2002-01-29 Sugen Inc Pyrrole substituted 2-indolinone protein kinase inhibitors
JP2002532503A (en) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー 4,5-Pyrazinooxindole as a protein kinase inhibitor
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
BR9916327A (en) 1998-12-17 2001-09-18 Hoffmann La Roche 4-alkenyl (and alkynyl) oxindols as inhibitors of cyclin-dependent kinases, in particular, cdk2
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US20070021366A1 (en) * 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
JPWO2006115135A1 (en) 2005-04-21 2008-12-18 アステラス製薬株式会社 Treatment for irritable bowel syndrome
AR059265A1 (en) 2006-02-07 2008-03-19 Astrazeneca Ab ESPIRO COMPOUNDS CONDENSED WITH INHIBITORY ACTIVITY IN THE VANILOID RECEIVER1 (VR1)
CN103274988B (en) * 2013-06-20 2016-04-13 河北大学 3-(cyano group-p-nitrobenzoyl support group)-2-indolone derivatives and preparation method and use thereof
CN115403566B (en) * 2022-09-21 2024-01-30 山东大学 3-substituted indol-2-one compound, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028906A1 (en) * 1979-11-13 1981-05-20 Imperial Chemical Industries Plc 1'-Substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones, processes for their manufacture and pharmaceutical compositions thereof
EP0304493A1 (en) * 1987-03-11 1989-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028906A1 (en) * 1979-11-13 1981-05-20 Imperial Chemical Industries Plc 1'-Substituted-spiro(imidazolidine-4,3'-indoline)-2,2',5-triones, processes for their manufacture and pharmaceutical compositions thereof
EP0304493A1 (en) * 1987-03-11 1989-03-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.E. RIVIER et al.: "Peptides: Chemistry, Structure and Biology. Proceedings of the Eleventh American Peptide Symposium, La Jolla, California, 9-14 July 1989", D.C. HEIMBROOK et al.: "Design and evaluation of novel gastrin-releasing peptide antagonists for the treatment of small cell lung cancer", 1990, ESCOM, Leiden, NL, pages 56-59, see the whole document (cited in the application) *

Also Published As

Publication number Publication date
IE913732A1 (en) 1992-05-22
WO1992007830A2 (en) 1992-05-14
PT99350A (en) 1992-10-30

Similar Documents

Publication Publication Date Title
WO1992007830A3 (en) Oxindole peptide antagonists
TR200000151T2 (en) New combinations.
ZA981936B (en) Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
TR200000197T2 (en) New combinations
CU23126A3 (en) INHIBITION OF KINASA RAF USING REPLACED HETEROCICLICAL UREAS
CA2245142A1 (en) New phenanthridines
AU6613896A (en) Chemical compounds
TR200101567T2 (en) New triazolo (4.5-D) pyrimidine compositions.
ZA9710796B (en) Oxyiminopregnanecarbolactones.
YU19499A (en) Benzonaphthyridines as bronchial therapeutics
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
ATE38227T1 (en) PHARMACOLOGICALLY ACTIVE DERIVATIVES OF PYRIDO(1,5)BENZODIAZEPINONE.
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
MY106781A (en) 6-benzoxazinyl- and 6-benzothiazinyl-2, 3, 4, 5- tetrahydropyridazin-3-ones.
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
CA2078129A1 (en) O6-benzylated guanine, guanosine and 2'- deoxyguanosine compounds possessing o6-alkylguanine-dna alkyltransferase depleting activity
BR0115121A (en) N - ((1,2,4) triazoloazinyl) thiophenesulfonamide compounds as herbicides
WO1987004923A3 (en) Aromatic amides absorbing the u.v.
TR200001182T2 (en) New carbonic acid derivatives, their production and uses.
TR200103237T2 (en) Imidazodiazepine derivative
TW216795B (en) 3-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazoline derivatives, the preparation and use thereof
MX9700813A (en) New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments.
AP8800109A0 (en) "Heterocyclic insecticides".
ES8800910A1 (en) Substituted quinazolinediones.
TR199901416T2 (en) Heterocyclic carbonicacyte térevleri.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase